NO20052307D0 - Blandinger og fremgangsmater for a modifisere toksiske effekter av proteinlignende forbindelser. - Google Patents
Blandinger og fremgangsmater for a modifisere toksiske effekter av proteinlignende forbindelser.Info
- Publication number
- NO20052307D0 NO20052307D0 NO20052307A NO20052307A NO20052307D0 NO 20052307 D0 NO20052307 D0 NO 20052307D0 NO 20052307 A NO20052307 A NO 20052307A NO 20052307 A NO20052307 A NO 20052307A NO 20052307 D0 NO20052307 D0 NO 20052307D0
- Authority
- NO
- Norway
- Prior art keywords
- protein
- compositions
- compounds
- methods
- toxic effects
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
- A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
- A61K47/6827—Ricin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Botany (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/282,935 US6960652B2 (en) | 1999-03-30 | 2002-10-29 | Compositions and methods for modifying toxic effects of proteinaceous compounds |
PCT/US2003/034425 WO2004040262A2 (en) | 2002-10-29 | 2003-10-29 | Compositions and methods for modifying toxic effects of proteinaceous compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20052307D0 true NO20052307D0 (no) | 2005-05-11 |
NO20052307L NO20052307L (no) | 2005-06-24 |
Family
ID=32926059
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20052307A NO20052307L (no) | 2002-10-29 | 2005-05-11 | Blandinger og fremgangsmater for a modifisere toksiske effekter av proteinlignende forbindelser. |
Country Status (12)
Country | Link |
---|---|
US (2) | US6960652B2 (no) |
EP (1) | EP1581242B1 (no) |
JP (1) | JP4845381B2 (no) |
KR (1) | KR101100628B1 (no) |
CN (1) | CN100531794C (no) |
AU (1) | AU2003295364B2 (no) |
BR (1) | BR0315864A (no) |
CA (1) | CA2503763A1 (no) |
IL (1) | IL168260A (no) |
MX (1) | MXPA05004713A (no) |
NO (1) | NO20052307L (no) |
WO (1) | WO2004040262A2 (no) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6960652B2 (en) * | 1999-03-30 | 2005-11-01 | Board Of Regents, The University Of Texas System | Compositions and methods for modifying toxic effects of proteinaceous compounds |
US7175848B1 (en) * | 2000-09-22 | 2007-02-13 | Board Of Regents, The University Of Texas System | Ricin A chain mutants lacking enzymatic activity as vaccines to protect against aerosolized ricin |
US6869787B2 (en) * | 2002-02-27 | 2005-03-22 | The United States Of America As Represented By The Secretary Of The Army | Ricin vaccine and methods of making and using thereof |
US9453251B2 (en) | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
WO2005052129A2 (en) * | 2003-11-25 | 2005-06-09 | Anjin Corporation | Diptheria toxin variant |
KR20070003934A (ko) * | 2004-03-05 | 2007-01-05 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템 |
EP2412816B1 (en) | 2004-07-26 | 2014-12-03 | Pfenex Inc. | Process for improved protein expression by strain engineering |
US9580719B2 (en) * | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
CA2685326A1 (en) * | 2007-04-27 | 2008-11-06 | Dow Global Technologies Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
US20090010966A1 (en) * | 2007-06-21 | 2009-01-08 | Angelica Therapeutics, Inc. | Modified diphtheria toxins |
WO2009110944A1 (en) * | 2008-02-29 | 2009-09-11 | Angelica Therapeutics, Inc. | Modified toxins |
WO2012011992A2 (en) * | 2010-04-22 | 2012-01-26 | The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of Walter Reed Army Institute Of Research | Ricin vaccine and methods of making and using thereof |
US10059750B2 (en) | 2013-03-15 | 2018-08-28 | Angelica Therapeutics, Inc. | Modified toxins |
CN108061798B (zh) * | 2016-11-07 | 2019-11-08 | 国药中生生物技术研究院有限公司 | 检测HBsAg/anti-HBs复合物体系中有效成分的量的方法和应用 |
WO2018126499A1 (zh) * | 2017-01-05 | 2018-07-12 | 深圳迈瑞生物医疗电子股份有限公司 | 网织红细胞模拟粒子、血小板模拟粒子制备方法及质控物 |
CN110904135B (zh) * | 2019-12-30 | 2021-08-13 | 苏州珀罗汀生物技术有限公司 | 蛋白质基础表达体系、合成系统及制备方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4792447A (en) | 1981-07-23 | 1988-12-20 | Board Of Regents, The University Of Texas System | Anti-immunoglobulin toxin conjugates useful in the treatment of B cell tumors |
US4664911A (en) | 1983-06-21 | 1987-05-12 | Board Of Regents, University Of Texas System | Immunotoxin conjugates employing toxin B chain moieties |
EP0170697B1 (en) * | 1984-02-08 | 1991-10-23 | Cetus Oncology Corporation | Toxin conjugates |
US5045451A (en) | 1988-10-26 | 1991-09-03 | Board Of Regents | Methods for screening antibodies for use as immunotoxins |
US5730978A (en) | 1989-09-01 | 1998-03-24 | Fred Hutchinson Cancer Research Center | Inhibition of lymphocyte adherence with α4β1-specific antibodies |
US5767072A (en) | 1989-09-14 | 1998-06-16 | Board Of Regents, The University Of Texas System | Therapeutic compositions comprising a CD4 peptide and methods of treatment of HIV infections |
US5686072A (en) | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
US5578706A (en) | 1993-11-04 | 1996-11-26 | Board Of Regents, The University Of Texas | Methods and compositions concerning homogenous immunotoxin preparations |
US5821231A (en) | 1993-12-06 | 1998-10-13 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using same |
US5770573A (en) | 1993-12-06 | 1998-06-23 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
AU693143B2 (en) | 1993-12-06 | 1998-06-25 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
US5510332A (en) | 1994-07-07 | 1996-04-23 | Texas Biotechnology Corporation | Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor |
US5688781A (en) | 1994-08-19 | 1997-11-18 | Bristol-Myers Squibb Company | Method for treating vascular leak syndrome |
US5811391A (en) | 1994-08-25 | 1998-09-22 | Cytel Corporation | Cyclic CS-1 peptidomimetics, compositions and methods of using same |
CH688362B5 (fr) * | 1995-03-28 | 1998-02-27 | Ebauchesfabrik Eta Ag | Pièce d'horlogerie électronique analogique à disque de quantième multifonctionnel. |
US6960652B2 (en) * | 1999-03-30 | 2005-11-01 | Board Of Regents, The University Of Texas System | Compositions and methods for modifying toxic effects of proteinaceous compounds |
WO2000058456A2 (en) | 1999-03-30 | 2000-10-05 | Board Of Regents, The University Of Texas System | Compositions and methods for modifying toxic effects of proteinacious compounds |
-
2002
- 2002-10-29 US US10/282,935 patent/US6960652B2/en not_active Expired - Lifetime
-
2003
- 2003-10-29 EP EP03786548A patent/EP1581242B1/en not_active Expired - Lifetime
- 2003-10-29 WO PCT/US2003/034425 patent/WO2004040262A2/en active Application Filing
- 2003-10-29 MX MXPA05004713A patent/MXPA05004713A/es active IP Right Grant
- 2003-10-29 CN CNB2003801048934A patent/CN100531794C/zh not_active Expired - Fee Related
- 2003-10-29 BR BR0315864-0A patent/BR0315864A/pt not_active IP Right Cessation
- 2003-10-29 JP JP2004548586A patent/JP4845381B2/ja not_active Expired - Fee Related
- 2003-10-29 AU AU2003295364A patent/AU2003295364B2/en not_active Ceased
- 2003-10-29 KR KR1020057007685A patent/KR101100628B1/ko not_active IP Right Cessation
- 2003-10-29 CA CA002503763A patent/CA2503763A1/en not_active Abandoned
-
2005
- 2005-04-27 IL IL168260A patent/IL168260A/en not_active IP Right Cessation
- 2005-05-11 NO NO20052307A patent/NO20052307L/no not_active Application Discontinuation
- 2005-10-31 US US11/263,537 patent/US7452971B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2503763A1 (en) | 2004-05-13 |
WO2004040262A3 (en) | 2004-08-05 |
NO20052307L (no) | 2005-06-24 |
WO2004040262A8 (en) | 2004-10-07 |
JP4845381B2 (ja) | 2011-12-28 |
MXPA05004713A (es) | 2005-08-03 |
BR0315864A (pt) | 2005-09-27 |
IL168260A (en) | 2012-01-31 |
KR20050090980A (ko) | 2005-09-14 |
EP1581242A2 (en) | 2005-10-05 |
US7452971B2 (en) | 2008-11-18 |
AU2003295364B2 (en) | 2009-04-02 |
US20030143193A1 (en) | 2003-07-31 |
JP2006504773A (ja) | 2006-02-09 |
CN1723032A (zh) | 2006-01-18 |
CN100531794C (zh) | 2009-08-26 |
AU2003295364A1 (en) | 2004-05-25 |
WO2004040262A2 (en) | 2004-05-13 |
KR101100628B1 (ko) | 2012-01-03 |
EP1581242B1 (en) | 2012-08-01 |
US20060100135A1 (en) | 2006-05-11 |
US6960652B2 (en) | 2005-11-01 |
EP1581242A4 (en) | 2009-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20052307D0 (no) | Blandinger og fremgangsmater for a modifisere toksiske effekter av proteinlignende forbindelser. | |
IS7543A (is) | Bensóþíadíasepínafleiður, aðferðir til framleiðslu þeirra og lyfjablöndur sem innihalda þær | |
DE60333094D1 (de) | Verbindungen, zusammensetzungen und verfahren | |
DK1354873T3 (da) | Perindoaprilsalt og farmaceutiske sammensætninger indeholdende dette | |
DE60311929D1 (de) | Verpackungsanlage | |
DK1560826T3 (da) | Pyridopyrimidinonderivater, fremgangsmåde til fremstiling heraf og farmaceutiske sammensætninger indeholdende disse | |
DK1575948T3 (da) | Pyridodiaziner som plantefungicider | |
IS7585A (is) | Ný piperadín efnasambönd | |
DK1611115T3 (da) | Benzothiazolderivatforbindelser, sammensætninger og anvendelser deraf | |
DE60319264D1 (de) | Fungizide | |
DK1548110T3 (da) | Transglutaminase-producerende stamme | |
DE60216645D1 (de) | Antiulcus pflanzenzusammensetzung(en) | |
DK1572950T3 (da) | Enkeltdomæne TDF-relaterede forbindelser og analoger deraf | |
DE60333210D1 (de) | Desinfektionsmethode | |
BR0310113B1 (pt) | Composições pesticidas | |
ATE391128T1 (de) | Fungizide | |
FR2842503B1 (fr) | Banderoleuse | |
NO20044064L (no) | Fremgangmater og sammensetninger for gastrointestinal-toksisitet indusert av cytoablativ terapi | |
NO20041909L (no) | Nye forbindelser og sammensetninger som katepsin S-inhibitorer | |
IS7581A (is) | Lyfjasamsetning | |
DE60216332D1 (de) | Antioxydationsmittel aus natürlicher quelle | |
DE60327243D1 (de) | Fungizide | |
NO20054532D0 (no) | Fremgangsmater for a forhindre glukonoylering av proteiner | |
DE60330904D1 (de) | Lisches bauteil | |
NO20052752D0 (no) | Oromukosalpreparat og fremgangsmate for fremstilling derav. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |